Prospective Multicenter Registry Study of Multiple System Atrophy in China
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-75
SponsorPeking University First Hospital
About this trial
Multiple system atrophy is a rare, rapidly progressive neurodegenerative disease characterized by variable combinations of parkinsonism, cerebellar ataxia, and autonomic dysfunction. Existing natural history studies from North America, Europe, and Japan suggest that clinical phenotypes and disease progression may differ across populations. However, comprehensive multicenter prospective data from Chinese patients with multiple system atrophy remain limited.
This prospective multicenter registry study aims to describe the clinical characteristics, longitudinal progression, and outcomes of Chinese patients with multiple system atrophy, to identify factors associated with disease progression and prognosis, and to establish a longitudinal cohort for future biomarker validation and clinical trial design.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients with clinically established or clinically probable multiple system atrophy according to the 2022 Movement Disorder Society diagnostic criteria; or
Patients with clinically established or clinically probable Parkinson disease according to the Movement Disorder Society diagnostic criteria; or
Healthy controls or controls without hereditary or neurodegenerative diseases who voluntarily agree to participate.
Age between 40 and 75 years.
Disqualifiers
Parkinsonism that cannot be classified as Parkinson disease or multiple system atrophy at the time of evaluation.
Clinical suspicion or diagnosis of other atypical parkinsonian syndromes, including progressive supranuclear palsy, dementia with Lewy bodies, or corticobasal syndrome.
Secondary parkinsonism due to intracranial space-occupying lesions, normal pressure hydrocephalus, drug-induced parkinsonism, or other identifiable causes.
Comorbid diseases that may substantially affect autonomic function, such as diabetic peripheral neuropathy or amyloidosis.
Trial population
Patients with MSA or PD who visited the outpatient department or wards of tertiary hospitals. Those who voluntarily participated, along with the family members of healthy individuals without neurodegenerative diseases, served as healthy controls.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
214 Participants
are grouped into 3 trial groupsGroup A: MSA
Group B: PD
Group C: HC
Trial outcomes
Primary outcomes
1
Change in disease severity
Change in disease severity as measured by the Unified Multiple System Atrophy Rating Scale over longitudinal follow-up.
Time frame
Baseline to up to 36 months after enrollment.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov